Ethanol, 2-[4-(methylsulfonyl)phenoxy]- | 96939-96-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Ethanol, 2-[4-(methylsulfonyl)phenoxy]-
• 英文别名: 2-(4-methylsulfonylphenoxy)ethanol
• CAS: 96939-96-7
• 化学式: C₉H₁₂O₄S
• 分子量: 216.26
• InChiKey: GJFJMACPXQCZMA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  72
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  异丙胺 、 Ethanol, 2-[4-(methylsulfonyl)phenoxy]- 以62%的产率得到
  参考文献：
  名称：

  SHANKLIN, JAMES R.

  摘要：

  DOI：
• 作为产物：
  描述：

  2-<4-Methylmercapto-phenoxy>-aethanol-(1) 以56%的产率得到
  参考文献：
  名称：

  SHANKLIN, JAMES R.

  摘要：

  DOI：

文献信息

• Substituted piperazines and diazepanes
  申请人：——

  公开号：US20040019039A1

  公开（公告）日：2004-01-29

  A novel class of substituted piperazines and diazepanes, pharmaceutical compositions comprising them and use thereof in the treatment of diseases and disorders related to the histamine H3 receptor. More particularly, the compounds are useful for the treatment of diseases and disorders in which an interaction with the histamine H3 receptor is beneficial.

  一种新型的取代哌嗪和二氮杂环庚烷类化合物，包括它们的药物组合物以及在治疗与组胺H3受体相关的疾病和紊乱中的应用。更具体地说，这些化合物对于治疗需要与组胺H3受体相互作用有益的疾病和紊乱是有用的。
• Beta-carbolines as growth hormone secretagogue receptor (GHSR) antagonists
  申请人：Crossley Roger

  公开号：US20050288316A1

  公开（公告）日：2005-12-29

  The present invention relates to compounds of Formula (I): wherein R 3 -R 8 , X, and Y are as described herein, processes for preparing the compounds, pharmaceutical compositions comprising the compounds, and use of the compounds and compositions in the prophylaxis or treatment of a GHSR receptor-related disorder. Examples of such disorders are obesity and related disorders such as diabetes type II, dyslipidemia and the metabolic syndrome Prader-Willi syndrome, cardiovascular diseases such as atherosclerotic vascular disease, angina pectoris, myocardial infarction and stroke, acromegaly and cancer, in particular breast, lung, prostate, thyroid and endocrine pituary carcinomas.

  本发明涉及式（I）的化合物：其中R3-R8，X和Y如本文所述，制备该化合物的方法，包含该化合物的药物组合物，以及在预防或治疗与GHSR受体相关的疾病中使用该化合物和组合物。此类疾病的例子包括肥胖症和相关疾病，如2型糖尿病，血脂异常和代谢综合征，普拉德-威利综合征，心血管疾病，如动脉粥样硬化、心绞痛、心肌梗死和中风，肢端肥大症和癌症，特别是乳腺癌、肺癌、前列腺癌、甲状腺癌和内分泌腺垂体癌。
• N-(Aryloxyalkyl)-N'-(aminoalkyl)thioureas
  申请人：A. H. Robins Company, Incorporated

  公开号：US04558155A1

  公开（公告）日：1985-12-10

  N-(Aryloxyalkyl)-N'-(aminoalkyl)ureas and thioureas having the formula: ##STR1## wherein R.sup.1 and R.sup.2 are hydrogen, loweralkyl, cycloalkyl, phenyl or phenyllower alkyl, and R.sup.3 and R.sup.4 are hydrogen, loweralkyl, phenyl and phenylalkyl or R.sup.3 and R.sup.4 taken together with the adjacent nitrogen form a heterocyclic residue are disclosed in a method of suppressing cardiac arrhythmias.

  本发明涉及一种抑制心律失常的方法，其中抑制剂为具有以下式子的N-(芳氧基烷基)-N'-(氨基烷基)脲和硫脲：##STR1## 其中R.sup.1和R.sup.2是氢、低碳基、环烷基、苯基或苯基低碳基，R.sup.3和R.sup.4是氢、低碳基、苯基和苯基烷基或R.sup.3和R.sup.4与相邻的氮一起形成杂环残基。
• N-(aryl-,aryloxy-,arylthio-arylsulfinyl-and arylsulfonyl-)alkyl-N,N'-(or
  申请人：A. H. Robins Company, Incorporated

  公开号：US04895840A1

  公开（公告）日：1990-01-23

  Novel N-(Aryl-,aryloxy-,arylthio-,arylsulfinyl-and arylsulfonyl-)alkyl-N,N'-(or N',N')alkylaminoalkyl ureas, thioureas and cyanoguanidines represented by the following formula: ##STR1## wherein Ar is aryl selected from the group consisting of 1- and 2-naphthyl, 2,3-dihydro-1H-inden-4(or 5)-yl,2-furanylmethyl,2-pyridinyl, phenyl and phenyl substituted by 1-3 radicals commonly used in the pharmaceutical art; (X).sub.d is oxygen, thio, sulfinyl, sulfonyl or d is zero; Z and W are each R or-(CH.sub.2).sub.m -NR.sup.1 R.sup.2 wtih the proviso that when Z is R, W is-(CH.sub.2).sub.m -NR.sup.1 R.sup.2 and when Z is-(CH.sub.2).sub.m -NR.sup.1 R.sup.2, W is R; B is carbonyl, thioxomethyl, or cyanoiminomethyl; R, R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are selected from the group consisting of hydrogen, loweralkyl, cycloalkyl, phenyl or phenyl-loweralkyl wherein phenyl may be substituted by 1-3 radicals commonly used in the pharmaceutical art; R.sup.1 and R.sup.2, and R.sup.3 and R.sup.4 may together with the adjacent nitrogen form the heterocyclic ring structure 1-homopiperidinyl, 4-morpholinyl, 1-piperazinyl, 4-substituted-1-piperazinyl, 1-pyrrolidinyl or 1-piperidinyl and the pharmaceutically acceptable salts thereof are disclosed. A pharmaceutical method for administering the compounds for their cardiac antiarrhythmic effect and pharmaceutical compositions for the treatment of cardiac arrhythmia are also disclosed.

  以下公式所代表的小说N-（芳基，芳氧基，芳硫基，芳基磺酰基和芳基亚磺酰基）-烷基-N，N' -（或N'，N'）烷基氨基烷基脲，硫脲和氰脲：##STR1## 其中Ar是从1-和2-萘基，2,3-二氢-1H-茚-4（或5）-基，2-呋喃甲基，2-吡啶基，苯基和苯基取代物中选择的芳基；（X）.sub.d是氧，硫，亚磺酰基，磺酰基或d为零；Z和W分别为R或-（CH.sub.2）.sub.m-NR.sup.1R.sup.2，但是当Z为R时，W为-（CH.sub.2）.sub.m-NR.sup.1R.sup.2，当Z为-（CH.sub.2）.sub.m-NR.sup.1R.sup.2时，W为R；B是羰基，硫代甲基或氰基亚甲基；R，R.sup.1，R.sup.2，R.sup.3和R.sup.4从氢，低碳基，环烷基，苯基或苯基-低碳基中选择，其中苯基可以被常用于制药的1-3个基团取代；R.sup.1和R.sup.2，R.sup.3和R.sup.4可以与相邻的氮一起形成杂环环结构1-同源哌啶基，4-吗啉基，1-哌嗪基，4-取代-1-哌嗪基，1-吡咯基或1-哌啶基及其制药可接受的盐。还公开了一种用于治疗心脏抗心律失常作用的化合物的药物方法以及用于治疗心脏心律失常的制药组合物。
• OXIME COMPOUNDS AND THE USE THEREOF
  申请人：Matsumura Akira

  公开号：US20090298878A1

  公开（公告）日：2009-12-03

  The invention relates to oxime compounds of Formula (I) and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein X is hydrogen, optionally substituted aryl, optionally substituted heteroaryl or the like; Y is CO, SO 2 , CR 3 R 4 or the like; Z is optionally substituted lower alkyl, optionally substituted aryl or the like; W is optionally substituted lower alkylene or optionally substituted lower alkenylene, R 3 and R 4 are each independently hydrogen, lower alkyl or the like; p is 0, 1, or 2 and q is 0, 1 or 2. The invention is also directed to the use compounds of Formula I to treat, prevent or ameliorate a disorder responsive to the blockade of calcium channels, and particularly N-type calcium channels. Compounds of the present invention are especially useful for treating pain.

  本发明涉及式(I)的肟化合物及其药学上可接受的盐、前药或溶剂，其中X为氢、可选取代芳基、可选取代杂环基或类似物；Y为CO、SO2、CR3R4或类似物；Z为可选取代的低烷基、可选取代的芳基或类似物；W为可选取代的低烷基或可选取代的低烯基，R3和R4各自独立地为氢、低烷基或类似物；p为0、1或2，q为0、1或2。本发明还涉及使用式(I)的化合物来治疗、预防或改善对钙通道封锁有反应的疾病，特别是N型钙通道。本发明的化合物特别适用于治疗疼痛。